Hemogenyx Pharmaceuticals Statistics

Total Valuation

Hemogenyx Pharmaceuticals has a market cap or net worth of GBP 16.10 million. The enterprise value is 17.20 million.

Market Cap	16.10M
Enterprise Value	17.20M

Important Dates

The next estimated earnings date is Friday, December 27, 2024.

Earnings Date	Dec 27, 2024
Ex-Dividend Date	n/a

Share Statistics

Hemogenyx Pharmaceuticals has 1.34 billion shares outstanding. The number of shares has increased by 20.74% in one year.

Current Share Class	n/a
Shares Outstanding	1.34B
Shares Change (YoY)	+20.74%
Shares Change (QoQ)	+0.95%
Owned by Insiders (%)	9.11%
Owned by Institutions (%)	38.16%
Float	1.21B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	5.26
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.32
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.43

Financial Position

The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.92.

Current Ratio	4.38
Quick Ratio	4.38
Debt / Equity	0.92
Debt / EBITDA	n/a
Debt / FCF	-0.55
Interest Coverage	-13.64

Financial Efficiency

Return on equity (ROE) is -155.97% and return on invested capital (ROIC) is -39.69%.

Return on Equity (ROE)	-155.97%
Return on Assets (ROA)	-37.79%
Return on Capital (ROIC)	-39.69%
Revenue Per Employee	n/a
Profits Per Employee	-304,847
Employee Count	17
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.00% in the last 52 weeks. The beta is 3.15, so Hemogenyx Pharmaceuticals's price volatility has been higher than the market average.

Beta (5Y)	3.15
52-Week Price Change	-50.00%
50-Day Moving Average	1.37
200-Day Moving Average	1.56
Relative Strength Index (RSI)	45.57
Average Volume (20 Days)	16,318,522

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-4.03M
Pretax Income	-5.19M
Net Income	-5.18M
EBITDA	-3.80M
EBIT	-4.03M
Earnings Per Share (EPS)	-0.00

Full Income Statement

Balance Sheet

The company has 1.64 million in cash and 2.78 million in debt, giving a net cash position of -1.14 million or -0.00 per share.

Cash & Cash Equivalents	1.64M
Total Debt	2.78M
Net Cash	-1.14M
Net Cash Per Share	-0.00
Equity (Book Value)	3.02M
Book Value Per Share	0.00
Working Capital	1.91M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.91 million and capital expenditures -104,124, giving a free cash flow of -5.02 million.

Operating Cash Flow	-4.91M
Capital Expenditures	-104,124
Free Cash Flow	-5.02M
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Hemogenyx Pharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-20.74%
Shareholder Yield	-20.74%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a